Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
3
×
biotech
boston
deals
gene therapy
new york blog main
san diego blog main
san francisco top stories
startups
vc
acetylon pharmaceuticals
ambys medicines
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
cell therapy
clinical trials
constellation pharmaceuticals
crispr
david walt
diagnostics
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
feng zhang
gene editing
genentech
holger willenbring
illumina
ipo
jeffrey tong
jennifer doudna
jim collins
What
diseases
3
×
medicines
3
×
ago
aiming
ambys
big
bio
biotech
biotechs
considering
control
create
crispr
data
deadly
deal
debuted
diagnostic
drug
dyne
early
editing
expected
experimental
eyes
fix
formed
future
gene
genetic
having
heats
high
human
humans
ipo
ipos
launch
launches
liver
Language
unset
Current search:
medicines
×
diseases
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?